NCT03125694View on ClinicalTrials.gov

Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

February 1, 2015

Primary Completion Date

April 1, 2017

Study Completion Date

April 1, 2017

Conditions
Uncontrolled Type 2 Diabetes Mellitus
Interventions
DRUG

Sitagliptin 100mg

Sitagliptin arm took sitagliptin 100 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks

DRUG

Pioglitazone 30 mg

Pioglitazone arm took pioglitazone 30 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks

Trial Locations (1)

Unknown

Tehran University of Medical Sciences, Tehran

All Listed Sponsors
lead

Tehran University of Medical Sciences

OTHER

NCT03125694 - Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea | Biotech Hunter | Biotech Hunter